A Gila monster PET scan found insulinomas with 95% accuracy, versus 65% for basic PET scans.
1. Travel Medicine Podcast 1216, “Journal Club: All Flesh, All Day,” focuses on pancreatic research and the Greek name “pancreas.”
2. Dr. J, an internal medicine doctor, and Dr. Santosh, a pediatric infectious disease doctor and researcher, host the journal-club discussion.
3. The episode asks what recent studies could change pancreatic cancer diagnosis, treatment, and prevention.
4. The hosts explain that pancreatic cancer is hard to detect because symptoms can be vague and screening is limited.
5. They say pancreatic cancer accounts for around 8% of cancer deaths and has about a 13% five-year survival rate.
6. A team at Canada’s Lawson Research Institute and London Health Science Centre Research Institute is preparing a two-year phase one safety trial.
7. That trial gives fecal transplantation capsules, described as “poop pills,” alongside standard chemotherapy.
8. The donors are screened tightly, with criteria including ages 18 to 50 and no antibiotics in at least six months.
9. The episode then turns to Gila monster venom chemistry and a PET scan for insulinomas.
10. The new scan uses exendin and reached 95% accuracy in 69 adult patients with suspected insulinoma.
11. The same section notes that standard PET scans found tumors 65% of the time.
12. The hosts connect exendin to GLP-1 drugs such as semaglutide and the later weight-loss use of those drugs.
13. Another segment introduces Pacman, short for protease activated magnetic nanosensor, as a blood test for pancreatic cancer.
14. Pacman uses a magnetic bead and fluorescent molecule that respond when proteases cleave the signal.
15. In a test of 178 people, Pacman identified 40 of 55 cancer cases and 120 of 123 non-cancer cases.
16. The hosts say Pacman could matter because it does not require specialized imaging equipment or high-tech facilities.
17. The tone stays conversational and joking, with frequent jokes about poop pills, lizard spit, and “penis” as a mistaken reading of PNAS.
18. The format is a medical-news journal club with two hosts narrating studies, caveats, and practical implications.
19. People interested in pancreatic cancer research, microbiome studies, and medical trivia would likely enjoy it.
20. People wanting a tightly edited, non-jokey clinical summary may skip it.
